Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Critical Assessment of Remdesivir

Author(s): Subhash Chandra*, Alka N. Choudhary, Santwana Palai, Abdur Rauf and Hassan Y. Aboul-Enein*

Volume 19, Issue 6, 2024

Published on: 31 October, 2023

Page: [648 - 660] Pages: 13

DOI: 10.2174/0115748855255004231001182927

Price: $65

Abstract

The COVID-19 pandemic that originated in Wuhan city, China, has affected every village in India. This has killed millions of people. This disease involves symptomatic and asymptomatic mutations. The purpose of this review was to assess the effectiveness of remdesivir particularly against SAR-CoV-2 (Coronaviridae family). The relevant works have been studied with respect to the drug's chemistry, mechanism of action, pharmacokinetics, pharmacodynamics, clinical data, and side effects. Remdesivir has been used in many cases of coronavirus-infected patients because it has been proven to possess beneficial effects; however, significant adverse effects have also been reported. Remdesivir has been reported to help in lowering the disease's high fatality rate. However, the WHO has warned against using the medicine because there is no clinical data to support its therapeutic efficacy.

Keywords: Coronaviruses, COVID-19, Ebola, Nipah, remdesivir, SAR-CoV-2, US-FDA.

Erratum In:
A Critical Assessment of Remdesivir

« Previous Next »
Graphical Abstract

[1]
Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and paramyxoviruses. Sci Rep 2017; 7(1): 43395.
[http://dx.doi.org/10.1038/srep43395http://dx.doi.org/] [PMID: 28262699]
[2]
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Scic Transl Med 2017; 9(396): eaal3653.
[http://dx.doi.org/10.1126/scitranslmed.aal3653http://dx.doi.org/] [PMID: 28659436]
[3]
Lamb YN. Remdesivir: First approval. Drugs 2020; 80(13): 1355-63.
[http://dx.doi.org/10.1007/s40265-020-01378-whttp://dx.doi.org/] [PMID: 32870481]
[4]
Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 2020; 6(5): 672-83.
[http://dx.doi.org/10.1021/acscentsci.0c00489] [PMID: 32483554]
[5]
Jordan R, Hogg A, Warren T, et al. Broad-spectrum investigational agent GS-5734 for the treatment of Ebola, MERS coronavirus and other pathogenic viral infections with high outbreak potential. Open Forum Infect Dis 2017; 4 (Suppl. 1): S737.
[http://dx.doi.org/10.1093/ofid/ofx180.008]
[6]
Madelain V, Baize S, Jacquot F, et al. Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nat Commun 2018; 9(1): 4013.
[http://dx.doi.org/10.1038/s41467-018-06215-z] [PMID: 30275474]
[7]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[8]
Nili A, Farbod A, Neishabouri A, Mozafarihashjin M, Tavakolpour S, Mahmoudi H. Remdesivir: A beacon of hope from ebola virus disease to COVID-19. Rev Med Virol 2020; 30(6): 1-13.
[http://dx.doi.org/10.1002/rmv.2133] [PMID: 33210457]
[9]
Kumar I. A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus disease. J Drug Deliv Ther 2021; 11(1): 121-9.
[http://dx.doi.org/10.22270/jddt.v11i1.4475] [PMID: 32277040]
[10]
Gao Y, Yan L, Huang Y. Structure of RNA-dependent RNA polymerase from 2019-nCoV, 565 a major antiviral drug target. Sci 2020; 368(6492): 779-82.
[http://dx.doi.org/10.1126/science.abb7498]
[11]
Sisay M. Available evidence and ongoing clinical trials of remdesivir: Could it be a promising therapeutic option for COVID-19? Front Pharmacol 2020; 11: 791.
[http://dx.doi.org/10.3389/fphar.2020.00791] [PMID: 32574236]
[12]
(a) Agostini ML, Andres EL, Sims AC, Graham RL. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio 2018; 6; 9(2): e00221-18.;
(b) Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health 2020; 9: 100128.
[http://dx.doi.org/10.1016/j.onehlt.2020.100128] [PMID: 32258351]
[13]
Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020; 295(20): 6785-97.
[http://dx.doi.org/10.1074/jbc.RA120.013679] [PMID: 32284326]
[14]
Humeniuk R, Mathias A, Kirby BJ, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor. Clin Pharmacokinet 2021; 60(5): 569-83.
[http://dx.doi.org/10.1007/s40262-021-00984-5] [PMID: 33782830]
[15]
Witkowski JT, Robins RK, Sidwell RW, Simon LN. Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972; 15(11): 1150-4.
[http://dx.doi.org/10.1021/jm00281a014] [PMID: 4347550]
[16]
Mehellou Y, Rattan HS, Balzarini J. The ProTide Prodrug Technology: From the Concept to the Clinic. J Med Chem 2018; 61(6): 2211-26.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00734] [PMID: 28792763]
[17]
Slusarczyk M, Serpi M, Pertusati F. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antivir Chem Chemother 2018; 26: 2040206618775243.
[http://dx.doi.org/10.1177/2040206618775243] [PMID: 29792071]
[18]
Yang K. What do we know about remdesivir drug interactions? Clin Transl Sci 2020; 13(5): 842-4.
[http://dx.doi.org/10.1111/cts.12815] [PMID: 32402130]
[19]
Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: Review of pharmacology, pre‐clinical data, and emerging clinical experience for COVID‐19. Pharmacotherapy 2020; 40(7): 659-71.
[http://dx.doi.org/10.1002/phar.2429] [PMID: 32446287]
[20]
Tempestilli M, Caputi P, Avataneo V, et al. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 2020; 75(10): 2977-80.
[http://dx.doi.org/10.1093/jac/dkaa239] [PMID: 32607555]
[21]
Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381(24): 2293-303.
[http://dx.doi.org/10.1056/NEJMoa1910993] [PMID: 31774950]
[22]
Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: From Ebola to COVID-19. Drugs Context 2020; 9(9) 2020-4-14.
[http://dx.doi.org/10.7573/dic.2020-4-14] [PMID: 32547625]
[23]
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 2020; 34(1): e00162-20.
[http://dx.doi.org/10.1128/CMR.00162-20] [PMID: 33055231]
[24]
Warren TK, Kane CD, Wells J, et al. Remdesivir is efficacious in rhesus monkeys exposed to aerosolized ebola virus. Sci Rep 2021; 11(1): 19458.
[http://dx.doi.org/10.1038/s41598-021-98971-0] [PMID: 34593911]
[25]
de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA 2020; 117(12): 6771-6.
[http://dx.doi.org/10.1073/pnas.1922083117] [PMID: 32054787]
[26]
Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020; 585(7824): 273-6.
[http://dx.doi.org/10.1038/s41586-020-2423-5] [PMID: 32516797]
[27]
Mechineni A, Kassab H, Manickam R. Remdesivir for the treatment of COVID 19: Review of the pharmacological properties, safety and clinical effectiveness. Expert Opin Drug Saf 2021; 20(11): 1299-307.
[http://dx.doi.org/10.1080/14740338.2021.1962284] [PMID: 34338121]
[28]
Higgs ES, Gayedyu-Dennis D, Fischer Ii WA, et al. PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs. Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. Clin Infect Dis 2021; 73(10): 1849-56.
[http://dx.doi.org/10.1093/cid/ciab215] [PMID: 33709142]
[29]
Lo MK, Albariño CG, Perry JK, et al. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proc Natl Acad Sci USA 2020; 117(43): 26946-54.
[http://dx.doi.org/10.1073/pnas.2012294117] [PMID: 33028676]
[30]
Ferner RE, Aronson JK. Remdesivir in COVID-19. BMJ-Brit Med J 2020; 369: 1610.
[http://dx.doi.org/10.1136/bmj.m1610] [PMID: 32321732]
[31]
Touafchia A, Bagheri H, Carrié D. Serious bradycardia and remdesivir for coronavirus 613 2019 (COVID-19): A new safety concerns. Clin Microbiol Infect 2021; 27(5): 791-e5-8.
[http://dx.doi.org/10.1016/j.cmi.2021.02.013] [PMID: 33647441]
[32]
Baracco GJ. Remdesivir use and hospital length of stay-the paradox of a clinical trial vs. real-life use. JAMA Netw Open 2021; 4(7): e2116057.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.16057] [PMID: 34264333]
[33]
Aleem A, Kothadia JP. Remdesivir. StatPearls Publishing 2021.
[34]
Hu WJ, Chang L, Yang Y, et al. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. Acta Pharmacol Sin 2021; 42(7): 1195-200.
[http://dx.doi.org/10.1038/s41401-020-00537-9] [PMID: 33041326]
[35]
Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis 2020; 35: 101647.
[http://dx.doi.org/10.1016/j.tmaid.2020.101647] [PMID: 32247927]
[36]
Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531(7594): 381-5.
[http://dx.doi.org/10.1038/nature17180] [PMID: 26934220]
[37]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[38]
Badgujar KC, Ram AH, Zanznay R, et al. Remdesivir for COVID-19: A review of pharmacology, mechanism of action, in-vitro activity and clinical use based on available case studies. J Drug Deliv Ther 2020; 10(4-s): 264-70.
[http://dx.doi.org/10.22270/jddt.v10i4-s.4313]
[39]
De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem Asian J 2019; 14(22): 3962-8.
[http://dx.doi.org/10.1002/asia.201900841] [PMID: 31389664]
[40]
Naik VR, Munikumar M, Ramakrishna U, et al. Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico approach. J Biomol Struct Dyn 2021; 39(13): 4701-14.
[http://dx.doi.org/10.1080/07391102.2020.1781694] [PMID: 32568620]
[41]
Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 2020; 55(4): 105933.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105933] [PMID: 32147516]
[42]
Szemiel AM, Merits A, Orton RJ, et al. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog 2021; 17(9): e1009929.
[http://dx.doi.org/10.1371/journal.ppat.1009929] [PMID: 34534263]
[43]
Padhi AK, Shukla R, Saudagar P, Tripathi T. High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: Implications for potential resistance. iScience 2020; 24(1): 101992.
[http://dx.doi.org/10.1016/j.isci.2020.101992] [PMID: 33490902]
[44]
Nevalainen OP, Horstia S, Laakkonen S, et al. Effect of remdesivir on recovery, quality of life, and long-COVID symptoms one year after hospitalization for COVID-19 infection: A randomized controlled solidarity finland trial. Open Forum Infect Dis 2022; 9 (Suppl. 2): ofac492-965.
[http://dx.doi.org/10.1093/ofid/ofac492.965]
[45]
Boglione L, Meli G, Poletti F, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: Does remdesivir have a protective effect? QJM 2022; 114(12): 865-71.
[http://dx.doi.org/10.1093/qjmed/hcab297] [PMID: 34850210]
[46]
Lo MK, Feldmann F, Gary JM, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 2019; 11(494): eaau9242.
[http://dx.doi.org/10.1126/scitranslmed.aau9242] [PMID: 31142680]
[47]
Gurley ES, Spiropoulou CF, de Wit E. Twenty years of Nipah virus research: Where do we go from here? J Infect Dis 2020; 221 (Suppl. 4): S359-62.
[http://dx.doi.org/10.1093/infdis/jiaa078] [PMID: 32392321]
[48]
Lo MK, Spengler JR, Krumpe LRH, et al. Griffithsin inhibits Nipah virus entry and fusion and can protect Syrian golden hamsters from lethal Nipah virus challenge. J Infect Dis 2020; 221 (Suppl. 4): S480-92.
[http://dx.doi.org/10.1093/infdis/jiz630] [PMID: 32037447]
[49]
Johnson K, Vu M, Freiberg AN. Recent advances in combating nipah virus. Fac Rev 2021; 10: 74.
[http://dx.doi.org/10.12703/r/10-74] [PMID: 34632460]
[50]
Eastin C, Eastin T. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 58(4): 711-2.
[http://dx.doi.org/10.1016/j.jemermed.2020.04.004]
[51]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[52]
Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug remdesivir: An update. Biomed Pharmacother 2020; 130: 110532.
[http://dx.doi.org/ 10.1016/j.biopha.2020.110532] [PMID: 32707440]
[53]
Maffei D, Choi S. Gilead announces results from phase 3 trial of investigational antiviral 666 remdesivir in patients with severe COVID-19. 2020. Available at [https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-r
[54]
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 2020; 324(11): 1048-57.
[http://dx.doi.org/10.1001/jama.2020.16349] [PMID: 32821939]
[55]
Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9(2): e00221-18.
[http://dx.doi.org/10.1128/mBio.00221-18] [PMID: 29511076]
[56]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease, 678 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese 679 center for disease control and prevention jama 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[57]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[58]
Ansems K, Grundeis F, Dahms K. Remdesivir for the treatment of COVID‐19. Cochrane Database Syst Rev 2021; 1(1): CD014962.
[http://dx.doi.org/10.1002/14651858.CD014962.pub2]
[59]
Rosa RB, Dantas WM, do Nascimento JCF, da Silva MV, de Oliveira RN, Pena LJ. In vitro and in vivo models for studying SARS-CoV-2, the etiological agent responsible for COVID-19 pandemic. Viruses 2021; 13(3): 379.
[http://dx.doi.org/10.3390/v13030379] [PMID: 33673614]
[60]
(a) Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029];
(b) Eastman RT, Roth JS, Brimacombe KR, Simeonov A. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19, ACS Cent Sci 2020; 27; 6(5): 672-83.
[61]
Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther 2020; 14(2): 73-6.
[http://dx.doi.org/10.5582/ddt.2020.01015] [PMID: 32378648]
[62]
Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: A randomized clinical trial. Intensive Care Med 2021; 47(11): 1258-70.
[http://dx.doi.org/10.1007/s00134-021-06507-x] [PMID: 34609549]
[63]
Dolin R, Hirsch MS. Remdesivir—an important first step. N Engl J Med 2020; 383(19): 1886-7.
[http://dx.doi.org/10.1056/NEJMe2018715] [PMID: 32459913]
[64]
Davies M, Osborne V, Lane S, et al. Remdesivir in treatment of COVID-19: A systematic benefit–risk assessment. Drug Saf 2020; 43(7): 645-56.
[http://dx.doi.org/10.1007/s40264-020-00952-1] [PMID: 32468196]
[65]
Ito K, Ohmagari N, Mikami A, Sugiura W. Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan. Glob Health Med 2020; 2(2): 96-101.
[http://dx.doi.org/10.35772/ghm.2020.01034] [PMID: 33330784]
[66]
Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci 2020; 41(6): 363-82.
[http://dx.doi.org/10.1016/j.tips.2020.03.006] [PMID: 32291112]
[67]
Sarvepalli D. Coronavirus disease 2019: A comprehensive review of etiology, pathogenesis, diagnosis, and ongoing clinical trials. Cureus 2020; 12(5): e8076.
[http://dx.doi.org/10.7759/cureus.8076] [PMID: 32542131]
[68]
Kow CS, Aldeyab M, Hasan SS. Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19. Eur J Clin Pharmacol 2021; 77(3): 435-7.
[http://dx.doi.org/10.1007/s00228-020-03008-6] [PMID: 33011825]
[69]
Abrams-Downey A, Saabiye J, Vidaurrazaga M. Investigational therapies for the treatment of COVID-19: Updates from ongoing clinical trials. Eur Urol Focus 2020; 6(5): 1028-31.
[http://dx.doi.org/10.1016/j.euf.2020.05.019] [PMID: 32563675]
[70]
Bimonte S, Crispo A, Amore A. Potential antiviral drugs for SARS-Cov-2 treatment: 709 preclinical findings and ongoing clinical research. In Vivo 2020; 34(3) (suppl.): 1597-602.
[http://dx.doi.org/10.21873/invivo.11949] [PMID: 32503817]
[71]
Ma Z, Liu J, Pan Q. Overwhelming COVID-19 clinical trials: Call for prospective meta-analyses. Trends Pharmacol Sci 2020; 41(8): 501-3.
[http://dx.doi.org/10.1016/j.tips.2020.05.002] [PMID: 32471655]
[72]
Bonini S, Maltese G. COVID-19 Clinical trials: Quality matters more than quantity. Allergy 2020; 75(10): 2542-7.
[http://dx.doi.org/10.1111/all.14409] [PMID: 32434272]
[73]
Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Health 2021; 9: 123-7.
[http://dx.doi.org/10.1016/j.cegh.2020.07.011] [PMID: 32838064]
[74]
Wang X, Guan Y. COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev 2021; 41(1): 5-28.
[http://dx.doi.org/10.1002/med.21728] [PMID: 32864815]

Rights & Permissions Print Cite
Article Metrics
44
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy